Opko Health Inc (OPK) Shares are Down -7.22%

Opko Health Inc (OPK) : During the past 4 weeks, traders have been relatively bearish on Opko Health Inc (OPK), hence the stock is down -8.15% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.61% relative to the S&P 500. The 4-week change in the price of the stock is -8.34% and the stock has fallen -7.22% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 7.63% and the fifty day Moving Average is 6.45%. Opko Health, Inc. has dropped 12.48% during the last three month period . Year-to-Date the stock performance stands at -9.25%.

Opko Health Inc (OPK) : The consensus price target for Opko Health Inc (OPK) is $15.67 for the short term with a standard deviation of $5.13. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $20, however, the pessimist price target for the company is $10.


Opko Health Inc (NYSE:OPK): stock turned positive on Friday. Though the stock opened at $9.09, the bulls momentum made the stock top out at $9.28 level for the day. The stock recorded a low of $9 and closed the trading day at $9.12, in the green by 1.00%. The total traded volume for the day was 3,116,659. The stock had closed at $9.03 in the previous days trading.

OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *